微芯生物(688321.SH):預計上半年淨利潤約爲3006萬元
格隆匯7月17日丨微芯生物(688321.SH)公佈2025年半年度業績預告,經公司財務部門初步測算:1.預計2025年半年度實現營業收入約爲40,729.00萬元,同比增加35%。2.預計2025年半年度實現歸屬於母公司所有者的淨利潤約爲3,006.00萬元,同比增加173%。3.預計2025年半年度實現扣除非經常性損益後歸屬母公司所有者的淨利潤約爲2,119.00萬元,同比增加145%。
本報告期內,公司產品西達本胺瀰漫大B細胞淋巴瘤適應症新進醫保,西格列他鈉銷售策略優化且“糖肝共管”獨特優勢得到市場認可,因此兩款產品銷量大幅增長。2025年第二季度公司營收預計同比增長43%,環比增長51%,歸屬母公司所有者的淨利潤實現扭虧。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.